Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P. Eriksson BI, et al. Among authors: dahl oe. Thromb Res. 2007;120(5):685-93. doi: 10.1016/j.thromres.2006.12.025. Epub 2007 Feb 12. Thromb Res. 2007. PMID: 17292948 Clinical Trial.
Low-molecular-weight heparin for hip fracture patients treated with osteosynthesis: should thromboprophylaxis start before or after surgery? An observational study of 45,913 hip fractures reported to the Norwegian Hip Fracture Register.
Leer-Salvesen S, Dybvik E, Engesaeter LB, Dahl OE, Gjertsen JE. Leer-Salvesen S, et al. Among authors: dahl oe. Acta Orthop. 2018 Dec;89(6):615-621. doi: 10.1080/17453674.2018.1519101. Epub 2018 Oct 17. Acta Orthop. 2018. PMID: 30328746 Free PMC article.
123 results